1. P04.51 TERT promoter mutation-driven TERT activation is mediated by ETS1 in BRAF V600E mutated glioma. (19th September 2018) Authors: Gabler, L; Gojo, J; Lötsch, D; Kirchhofer, D; van Schoonhoven, S; Stojanovic, M; Schmidt, H M; Ensle, D; Czech, T; Haberler, C; Slavc, I; Spiegl-Kreinecker, S; Berger, W Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii290 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P10.08.A Lipogenesis inhibition by fatostatin shows effectiveness in glioblastoma models highly expressing fatty acid synthase (FASN). (5th September 2022) Authors: Kastler, L; Neumayer, K; Laaber, M; Roschger, C; Lenz, S; Lötsch-Gojo, D; Berger, W; Gruber, A; Spiegl-Kreinecker, S Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P14.04.A TrackingTERTpromoter andIDH1mutations in liquid biopsies - suitable biomarkers for disease monitoring in glioma patients?. (5th September 2022) Authors: Bruckner, K; Madlener, S; Lang, A; Kiesel, B; Furtner-Srajer, J; Hainfellner, J; Haberler, C; Spiegl-Kreinecker, S; Dorfer, C; Slavc, I; Gojo, J; Rössler, K; Lötsch-Gojo, D Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P18.06.B ETS-Transcription Factor inhibitors are effective inTERT promoter mutated meningioma cells in vitro. (5th September 2022) Authors: Neumayer, K; Kastler, L; Laaber, M; Roschger, C; Lenz, S; Lötsch-Gojo, D; Berger, W; Gruber, A; Spiegl-Kreinecker, S Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗